CureVac B.V.(CVAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CVAC CureVac B.V.

Trading 11-15 14:44:59 EST

2.53

-0.14

-5.43%

High2.68	Low2.50	Vol885.58K
Open2.66	D1 Closing2.67	Amplitude6.55%
Mkt Cap566.39M	Tradable Cap311.93M	Total Shares224.31M
T/O2.26M	T/O Rate0.72%	Tradable Shares123.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CVAC","market":"US","secType":"STK","nameCN":"CureVac B.V.","latestPrice":2.525,"timestamp":1731699897825,"preClose":2.67,"halted":0,"volume":885577,"delay":0,"floatShares":123537308,"shares":224314013,"eps":-1.33301,"marketStatus":"Trading","change":-0.145,"latestTime":"11-15 14:44:59 EST","open":2.66,"high":2.675,"low":2.5,"amount":2264706.1646979,"amplitude":0.065543,"askPrice":2.53,"askSize":500,"bidPrice":2.52,"bidSize":1054,"shortable":3,"etf":0,"ttmEps":-1.33301,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1731704400000},"marketStatusCode":2,"adr":0,"listingDate":1597377600000,"exchange":"NASDAQ","adjPreClose":2.67,"preHourTrading":{"tag":"盘前","latestPrice":2.67,"preClose":2.67,"latestTime":"09:14 EST","volume":2680,"amount":7179.600204,"timestamp":1731680083175},"postHourTrading":{"tag":"盘后","latestPrice":2.71,"preClose":2.67,"latestTime":"19:18 EST","volume":4392,"amount":11739.46,"timestamp":1731629898938},"volumeRatio":1.662011,"impliedVol":2.3501,"impliedVolPercentile":0.9325},"requestUrl":"/m/hq/s/CVAC","defaultTab":"news","newsList":[{"id":"2483852534","title":"CureVac NV reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483852534","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483852534?lang=en_us&edition=fundamental","pubTime":"2024-11-14 04:22","pubTimestamp":1731529363,"startTime":"0","endTime":"0","summary":"CureVac NV reports results for the quarter ended September 30 - Earnings SummaryCureVac NV CVAC.OQ reported quarterly adjusted earnings of 1.50 per share for the quarter ended September 30, higher tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL8N3MK2SV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVAC"],"gpt_icon":1},{"id":"2483023943","title":"CureVac NV (CVAC) Q3 2024 Earnings Call Highlights: Strong Financial Performance and Strategic ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483023943","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483023943?lang=en_us&edition=fundamental","pubTime":"2024-11-13 15:13","pubTimestamp":1731482038,"startTime":"0","endTime":"0","summary":"Revenue: EUR493.9 million for the third quarter, EUR520.7 million for the first nine months of 2024.Net Profit: EUR371.6 million for the third quarter, EUR229.4 million for the first nine months of 2024.Cash Position: EUR550.9 million at the end of the third quarter.Licensing Agreement: EUR400 million upfront payment from GSK, fully recognized as revenue in Q3 2024.Workforce Reduction: 30% reduction by the end of 2024, expected to decrease operational expenses by over 30% starting in 2025.R&D Expenses: Increased due to higher investments in oncology development programs and litigation expenses.General and Administrative Expenses: Decreased due to lower personnel expenses.GuruFocus has detected 5 Warning Signs with CVAC.CureVac NV  is advancing its oncology pipeline with promising preliminary data from a phase one study in glioblastoma, showing potential for mRNA technology in aggressive cancers.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/t.knfqtHPDCoBKrb3zCgGA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/eaca71e6f60561af24ae5f4c392e306b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/t.knfqtHPDCoBKrb3zCgGA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/eaca71e6f60561af24ae5f4c392e306b"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/curevac-nv-cvac-q3-2024-071358024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CVAC"],"gpt_icon":1},{"id":"2483063222","title":"CureVac Reports Surging Revenues and Profit Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2483063222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483063222?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:58","pubTimestamp":1731448682,"startTime":"0","endTime":"0","summary":"CureVac (CVAC) has released an update. CureVac N.V. has reported significant financial growth in the third quarter of 2024, with revenues surging t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/curevac-reports-surging-revenues-and-profit-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/curevac-reports-surging-revenues-and-profit-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","CVAC","BK4548","BK4139"],"gpt_icon":0},{"id":"2483063228","title":"CureVac’s Financial Upsurge and Strategic Restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=2483063228","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483063228?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:55","pubTimestamp":1731448542,"startTime":"0","endTime":"0","summary":"CureVac (CVAC) has released an update. CureVac has reported a transformative third quarter with a strengthened cash position of €551 million follow...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/curevacs-financial-upsurge-and-strategic-restructuring?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/curevacs-financial-upsurge-and-strategic-restructuring?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4548","BK4551","CVAC"],"gpt_icon":0},{"id":"2482089687","title":"CureVac reports Q3 revenue EUR 493.9M vs. EUR 16.5M last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2482089687","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482089687?lang=en_us&edition=fundamental","pubTime":"2024-11-12 22:46","pubTimestamp":1731422794,"startTime":"0","endTime":"0","summary":"Commenting on the quarter Dr. Alexander Zehnder, Chief Executive Officer of CureVac (CVAC) said: “The third quarter was truly transformative for Cu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/curevac-reports-q3-revenue-eur-493-9m-vs-eur-16-5m-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/curevac-reports-q3-revenue-eur-493-9m-vs-eur-16-5m-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CVAC","BK4548","BK4551","BK4139"],"gpt_icon":0},{"id":"2482008963","title":"CureVac on track with 30% workforce reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2482008963","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482008963?lang=en_us&edition=fundamental","pubTime":"2024-11-12 22:46","pubTimestamp":1731422786,"startTime":"0","endTime":"0","summary":"CureVac (CVAC) made meaningful progress in restructuring its operations during the third quarter by implementing significant cost-cutting measures....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/curevac-on-track-with-30-workforce-reduction?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/curevac-on-track-with-30-workforce-reduction?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4551","BK4548","CVAC"],"gpt_icon":0},{"id":"2482470695","title":"CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482470695","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482470695?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:20","pubTimestamp":1731414000,"startTime":"0","endTime":"0","summary":"Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter. 400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to 551 million; expected cash runway re-affirmed into 2028. CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNO. New off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025. New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccines. Positive Phase 2 data from seasonal influenza program licensed to GSK demonstrated strong immune responses against challenging influenza B as well as A strains; program progressing to Phase 3, which will be associated with significant milestone payment. Corporate redesign on track with 30% workforce reduction, expected to yield signi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bx7cdeRNxEwazNcDWucEIw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/a0ea1b5efd3fe31259aaba2e79e18980","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bx7cdeRNxEwazNcDWucEIw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/a0ea1b5efd3fe31259aaba2e79e18980"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/curevac-announces-financial-results-third-122000623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","BK4548","CVAC","BK4080","SITC","CTA","CMO","BK4551","BK4139"],"gpt_icon":1},{"id":"2482147703","title":"CureVac Q3 Sales EUR493.90M Beat EUR103.76M Estimate; Represents 2,897% Increase From EUR 16.5M Prior Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2482147703","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482147703?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:14","pubTimestamp":1731413657,"startTime":"0","endTime":"0","summary":"CureVac Q3 Sales EUR493.90M Beat EUR103.76M Estimate; Represents 2,897% Increase From EUR 16.5M Prior Year","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41897033/curevac-q3-sales-eur493-90m-beat-eur103-76m-estimate-represents-2-897-increase-from-eur-16-5m-prior","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"CureVac Q3 Sales EUR493.90M Beat EUR103.76M Estimate; Represents 2,897% Increase From EUR 16.5M Prior Year","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVAC"],"gpt_icon":0},{"id":"2482482504","title":"CureVac NV  expected to post earnings of 56 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482482504","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482482504?lang=en_us&edition=fundamental","pubTime":"2024-11-09 00:58","pubTimestamp":1731085085,"startTime":"0","endTime":"0","summary":"CureVac NV  expected to post earnings of56cents a share - Earnings Preview CureVac NV CVAC.OQ, CVAC.O is expected to show a rise in quarterly revenue when it reports  results on November 12 for the pe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF2YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVAC"],"gpt_icon":1},{"id":"2481904535","title":"CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904535","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904535?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:30","pubTimestamp":1730982600,"startTime":"0","endTime":"0","summary":"TBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V.  , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid , will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:. This press release contains statements that constitute \"forward looking statements\" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V.  r","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bx7cdeRNxEwazNcDWucEIw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/a0ea1b5efd3fe31259aaba2e79e18980","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bx7cdeRNxEwazNcDWucEIw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/a0ea1b5efd3fe31259aaba2e79e18980"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/curevac-report-third-quarter-first-123000175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CVAC","BK4548","BK4551","BK4139"],"gpt_icon":1},{"id":"2481568116","title":"CureVac’s Latest mRNA Advances Spark Investor Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2481568116","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481568116?lang=en_us&edition=fundamental","pubTime":"2024-11-05 05:47","pubTimestamp":1730756873,"startTime":"0","endTime":"0","summary":"CureVac (CVAC) has released an update. CureVac is set to unveil promising new data from its mRNA-based cancer vaccine study at the upcoming mRNA He...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/curevacs-latest-mrna-advances-spark-investor-interest?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/curevacs-latest-mrna-advances-spark-investor-interest?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","SPKL","BK4548","BK4139","CVAC"],"gpt_icon":0},{"id":"2481556815","title":"CureVac Appoints New CFO to Drive Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2481556815","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481556815?lang=en_us&edition=fundamental","pubTime":"2024-11-05 05:47","pubTimestamp":1730756842,"startTime":"0","endTime":"0","summary":"CureVac (CVAC) has released an update. CureVac has appointed Axel Sven Malkomes as their new Chief Financial Officer, marking a strategic move as t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/curevac-appoints-new-cfo-to-drive-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/curevac-appoints-new-cfo-to-drive-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4551","BK4139","CVAC"],"gpt_icon":0},{"id":"2481653560","title":"CureVac Appoints Axel Sven Malkomes as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2481653560","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481653560?lang=en_us&edition=fundamental","pubTime":"2024-11-05 00:24","pubTimestamp":1730737494,"startTime":"0","endTime":"0","summary":"CureVac (CVAC) said Monday it has appointed Axel Sven Malkomes as its chief financial officer, starting Nov. 11.Malkomes most recently worked as CFO at Cardior Pharmaceuticals, the company said.Price: 2.74, Change: -0.02, Percent Change: -0.91","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4551","CVAC","BK4548","BK4139"],"gpt_icon":0},{"id":"2480047763","title":"CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2480047763","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480047763?lang=en_us&edition=fundamental","pubTime":"2024-11-04 20:20","pubTimestamp":1730722800,"startTime":"0","endTime":"0","summary":"Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformation. TBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V.  , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid , today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.Mr. Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries.\"Axel's appointment corresponds with a significant milestone in CureVac's evolution,\" said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. \"As we embark on an exciting new phase of corporate development, his extensive expertise and proven leadership in the life sciences sector will be instrumental. Axel will play a key role i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bx7cdeRNxEwazNcDWucEIw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/a0ea1b5efd3fe31259aaba2e79e18980","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bx7cdeRNxEwazNcDWucEIw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/a0ea1b5efd3fe31259aaba2e79e18980"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/curevac-strengthens-leadership-team-appointment-122000157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CVAC","TISI","BK4548","BK4139","BK4120","BK4551"],"gpt_icon":1},{"id":"2480030145","title":"CureVac: Names Sven Malkomes as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2480030145","media":"THOMSON REUTERS","labels":["Executive Changes","Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480030145?lang=en_us&edition=fundamental","pubTime":"2024-11-04 20:07","pubTimestamp":1730722043,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nFWN3MB133:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes,Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CVAC","BK4551","BK4548"],"gpt_icon":0},{"id":"2478100820","title":"CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2478100820","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478100820?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:10","pubTimestamp":1730117400,"startTime":"0","endTime":"0","summary":"TBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V.  , a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid , today announced poster presentations at the Society for Immunotherapy of Cancer  39th Annual Meeting, taking place November 8-10 in Houston, USA.CureVac will present, among other data, extended preliminary immunogenicity results from Part A of the dose escalation phase of its ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma. The presentation will expand on safety, tolerability and immunogenicity results of the CVGBM trial presented last month at the European Society for Medical Oncology  Congress, which demonstrated treatment with CVGBM monotherapy successfully induced cancer antigen-specific T-cell responses in 77% of evaluable patients, 84% of which were de novo.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bx7cdeRNxEwazNcDWucEIw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/a0ea1b5efd3fe31259aaba2e79e18980","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bx7cdeRNxEwazNcDWucEIw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/a0ea1b5efd3fe31259aaba2e79e18980"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/curevac-present-society-immunotherapy-cancer-121000043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","CVAC","BK4548","BK4139","BK4231","BK4551","SITC"],"gpt_icon":1},{"id":"2474236698","title":"CureVac: Back To Square One","url":"https://stock-news.laohu8.com/highlight/detail?id=2474236698","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474236698?lang=en_us&edition=fundamental","pubTime":"2024-10-09 06:17","pubTimestamp":1728425822,"startTime":"0","endTime":"0","summary":"Today, we're circling back to a development company called CureVac N.V.The company recently agreed to a deal with GSK plc, that involved a huge upfront payment, as well as potential milestone payouts ","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284442152/image_1284442152.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284442152/image_1284442152.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4725708-curevac-back-to-square-one","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","BK4551","BK4548","CVAC"],"gpt_icon":0},{"id":"2473406471","title":"Pfizer, BioNTech win lawsuit against CureVac over COVID vaccine patents in U.K.","url":"https://stock-news.laohu8.com/highlight/detail?id=2473406471","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473406471?lang=en_us&edition=fundamental","pubTime":"2024-10-08 23:01","pubTimestamp":1728399668,"startTime":"0","endTime":"0","summary":"Pfizer  and BioNTech  on Tuesday successfully convinced London's High Court to invalidate two patents held by rival CureVac  related to the messenger RNA  technology upon which the duo's blockbuster COVID-19 vaccine is based. The litigation is part of the U.K. segment of a broader legal battle between Pfizer , BioNTech , and CureVac , spanning countries from the U.S. to Germany.  Pfizer  and BioNTech , whose messenger-RNA-based COVID-19 vaccine Comirnaty was the first to win the U.S. regulatory nod in 2020, initially filed the lawsuit against the German vaccine developer in September 2022. Several lawsuits filed by CureVac  against its German rival BioNTech  in its home country had preceded the companies' U.K. lawsuit.","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1483938846/image_1483938846.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1483938846/image_1483938846.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4157042-pfizer-biontech-invalidate-curevac-covid-patents","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU0225771236.USD","LU0868494617.USD","LU0234572021.USD","LU0306806265.USD","BK4139","BK4588","LU1066053197.SGD","BK4533","LU1894683264.USD","PFE","LU0306807586.USD","LU0058720904.USD","BK4585","IE00BLSP4239.USD","LU0321505868.SGD","BK4534","LU1057294990.SGD","SG9999001176.SGD","BNTX","SG9999011175.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","SG9999002224.SGD","BK4548","IE000M9KFDE8.USD","LU0289739699.SGD","LU0122379950.USD","BK4551","LU0170899867.USD","BK4592","IE00B19Z3581.USD","IE00BBT3K403.USD","LU0985481810.HKD","LU1883839398.USD","BK4581","BK4568","SG9999003800.SGD","IE00BLSP4452.SGD","SG9999013999.USD","SGXZ57979304.SGD","SG9999002232.USD","LU0225284248.USD","LU1066051498.USD","SG9999001176.USD","LU0456855351.SGD","LU1023059063.AUD","LU0321505439.SGD","BK4535","BK4007","CVAC"],"gpt_icon":1},{"id":"2473238354","title":"Pfizer, BioNTech Win Legal Dispute Against CureVac's UK COVID Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2473238354","media":"MT Newswires Live","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473238354?lang=en_us&edition=fundamental","pubTime":"2024-10-08 19:23","pubTimestamp":1728386587,"startTime":"0","endTime":"0","summary":"Pfizer (PFE) and BioNTech (BNTX) successfully invalidated two patents held by CureVac (CVAC) in a ruling by London's High Court on Tuesday.The lawsuit, filed in September 2022, relates to messenger RN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999001176.USD","IE0002270589.USD","LU1057294990.SGD","SG9999003800.SGD","LU0306806265.USD","BK4585","IE000M9KFDE8.USD","PFE","IE00B19Z3B42.SGD","BK4592","LU0234572021.USD","LU0225771236.USD","BK4550","BK4533","LU1066053197.SGD","BK4139","BK4568","BK4551","LU0289739699.SGD","IE00BBT3K403.USD","LU1894683264.USD","BK4534","BK4548","LU1894683348.USD","SG9999002232.USD","LU0321505439.SGD","LU0225284248.USD","SG9999013999.USD","LU0058720904.USD","IE00BLSP4239.USD","IE00B19Z3581.USD","CVAC","LU0456855351.SGD","LU0321505868.SGD","IE00BLSP4452.SGD","SGXZ57979304.SGD","LU0868494617.USD","BNTX","LU0122379950.USD","SG9999001176.SGD","BK4588","LU1023059063.AUD","SG9999002224.SGD","LU1883839398.USD","LU0170899867.USD","BK7095","BK4535","BK4007","BK4581"],"gpt_icon":1},{"id":"2472326838","title":"CureVac N.V.'s (NASDAQ:CVAC) top owners are individual investors with 35% stake, while 31% is held by private equity firms","url":"https://stock-news.laohu8.com/highlight/detail?id=2472326838","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472326838?lang=en_us&edition=fundamental","pubTime":"2024-10-01 18:40","pubTimestamp":1727779210,"startTime":"0","endTime":"0","summary":"CureVac's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public. A total of 3 investors have a majority stake in the company with 52% ownership. Every investor in CureVac N.V.  should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 35% to be precise, is individual investors. Put another way, the group faces the maximum upside potential .Private equity firms, on the other hand, account for 31% of the company's stockholders.Let's take a closer look to see what the different types of shareholders can tell us about CureVac.While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-leve","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/curevac-n-v-nasdaq-cvac-104010164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","BK4585","LU2095319765.USD","MNQmain","LU2210149790.SGD","BK4551","LU2210150020.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD",".IXIC","QID","QLD","CVAC","SQQQ","PSQ","NDAQ","BK4112","BK4548","IE00B64PRP62.GBP","BK4139","BK4588","TQQQ","IE00BKPKM429.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.curevac.com","stockEarnings":[{"period":"1week","weight":-0.0565},{"period":"1month","weight":-0.0498},{"period":"3month","weight":-0.1759},{"period":"6month","weight":-0.235},{"period":"1year","weight":-0.5172},{"period":"ytd","weight":-0.3658}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.074507},{"month":2,"riseRate":0.25,"avgChangeRate":-0.078931},{"month":3,"riseRate":0.25,"avgChangeRate":-0.042891},{"month":4,"riseRate":0.5,"avgChangeRate":0.009789},{"month":5,"riseRate":0.75,"avgChangeRate":0.226595},{"month":6,"riseRate":0.25,"avgChangeRate":-0.165776},{"month":7,"riseRate":0.25,"avgChangeRate":-0.093754},{"month":8,"riseRate":0.25,"avgChangeRate":-0.027881},{"month":9,"riseRate":0,"avgChangeRate":-0.164639},{"month":10,"riseRate":0.2,"avgChangeRate":-0.117332},{"month":11,"riseRate":0.6,"avgChangeRate":0.26972},{"month":12,"riseRate":0,"avgChangeRate":-0.226567}],"exchange":"NASDAQ","name":"CureVac B.V.","nameEN":"CureVac B.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CureVac B.V.(CVAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CureVac B.V.(CVAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CureVac B.V.,CVAC,CureVac B.V.股票,CureVac B.V.股票老虎,CureVac B.V.股票老虎国际,CureVac B.V.行情,CureVac B.V.股票行情,CureVac B.V.股价,CureVac B.V.股市,CureVac B.V.股票价格,CureVac B.V.股票交易,CureVac B.V.股票购买,CureVac B.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CureVac B.V.(CVAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CureVac B.V.(CVAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction